TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20508011

Group type: EXPERIMENTAL
Intervention: Static progressive stretch brace
Number of subjects: 13

Group type: COMPARATOR
Intervention: Active stretching exercises
Number of subjects: 13
Study: 18972276

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (320/9 microg 4 times daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 16649833

Group type: EXPERIMENTAL
Intervention: Adherence with antipsychotic medication
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Nonadherence in the first year
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Adherence status
Number of subjects: 1906
Study: 14563970

Group type: EXPERIMENTAL
Intervention: 18F‐fluoromisonidazole PET imaging within 6 hours of stroke onset
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 18F‐fluoromisonidazole PET imaging after 6 hours of stroke onset
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 18F‐fluoromisonidazole PET imaging
Number of subjects: 19

Group type: COMPARATOR
Intervention: 15 age‐matched controls
Number of subjects: 19
Study: 10971268

Group type: EXPERIMENTAL
Intervention: PRO 160/120 (saw palmetto fruit and nettle root extract)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: PRO 160/120
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 431
Study: 8880834

Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fibromyalgia and RA patients
Number of subjects: 20
Study: 1403581

Group type: EXPERIMENTAL
Intervention: Methylene blue applied subgingivally for 7 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 7
Study: 3986895

Group type: EXPERIMENTAL
Intervention: Pizotifen (0.5 mg t.i.d.)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg b.i.d.)
Number of subjects: 35
Study: 31876175

Group type: EXPERIMENTAL
Intervention: Gamification intervention
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Gamification with primary care physician sharing
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control
Number of subjects: 196
Study: 29497289

Group type: EXPERIMENTAL
Intervention: Tiotropium delivered via HandiHaler® (18 μg once daily) or Respimat® Soft Mist™ (2.5 or 5 μg once daily)
Number of subjects: 17116
Study: 27116024

Group type: EXPERIMENTAL
Intervention: Three oral formulations of ciprofloxacin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ciprofloxacin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: In vitro ciprofloxacin release testing
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mechanistic absorption models
Number of subjects: 16
Study: 24330381

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ropivacaine 0.2%
Number of subjects: 30
Study: 22142495

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise programme
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study: 20400095

Group type: EXPERIMENTAL
Intervention: Low-dose eplerenone (25 mg daily)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Middle-dose eplerenone (25 mg twice daily)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: High-dose eplerenone (50 mg twice daily)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 18208957

Group type: EXPERIMENTAL
Intervention: Telehomecare units with peripheral devices (blood-pressure monitor, weight scale, glucometer, pulse oximeter) installed in patients' homes, monitored by nurse practitioners.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Telehomecare monitoring system
Number of subjects: 22
Study: 16200612

Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg orally once or twice daily)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Non-folic acid
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 668
Study: 14723396

Group type: EXPERIMENTAL
Intervention: Skinfold calipers
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Inexpensive plastic Fat Control calipers
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 332
Study: 10988305

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Preoperative autologous blood donation (PABD)
Number of subjects: 46
Study: 8902371

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheterization (PAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Technology assessment
Number of subjects: 0
Study: 1452369

Group type: EXPERIMENTAL
Intervention: Serum cortisol levels
Number of subjects: 70
Study: 6483504

Group type: EXPERIMENTAL
Intervention: DL-carnitine, 100 mg/kg/day for 4 days
Number of subjects: 132
Study: 30482254

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28549895

Group type: EXPERIMENTAL
Intervention: Needle-free jet lidocaine (J-tip) administration (0.25 mL of 2% lidocaine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Simultaneous lidocaine injection (0.5 mL of 1% lidocaine) with corticosteroid
Number of subjects: 100
Study: 25682258

Group type: EXPERIMENTAL
Intervention: Exposure to the film 'Into the wild'
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (no film exposure)
Number of subjects: 154
Study: 24104763

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) of propofol 10 mg/mL, initial targeted effect-site concentration 2 μg/mL
Number of subjects: 82

Group type: COMPARATOR
Intervention: Patient-controlled sedation (PCS) of propofol, single bolus 1 mL, lockout time set at zero
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Combination of propofol and alfentanil
Number of subjects: 82
Study: 20966170

Group type: EXPERIMENTAL
Intervention: G-PBSCs plus induction chemotherapy with cytarabine and mitoxantrone
Number of subjects: 58

Group type: COMPARATOR
Intervention: Induction chemotherapy with cytarabine and mitoxantrone (control group)
Number of subjects: 58
Study: 18324934

Group type: EXPERIMENTAL
Intervention: Intervention group (physicians received the Pressure System Model training)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Control group (physicians received usual residency training)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Intervention group (residents provided PA counselling)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Control group (residents provided PA counselling)
Number of subjects: 381
Study: 16420978

Group type: EXPERIMENTAL
Intervention: Anxiety-mediated gait adaptations
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Anxiety-mediated gait adaptations among older adults
Number of subjects: 28
Study: 12740515

Group type: EXPERIMENTAL
Intervention: Deep endotracheal suctioning (ETS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Shallow endotracheal suctioning (ETS)
Number of subjects: 22
Study: 11004288

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 20

Group type: COMPARATOR
Intervention: Timolol-XE
Number of subjects: 20
Study: 8793415

Group type: EXPERIMENTAL
Intervention: DHA supplementation (0, 0.2, 0.4, 0.9, 1.3 g DHA/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1335642

Group type: EXPERIMENTAL
Intervention: Single dose of hepatitis A vaccine (group 1)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Two doses given simultaneously (group 2)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Two doses at days 0 and 14 (group 3)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Two doses at days 0 and 28 (group 4)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Three doses at days 0, 7 and 21 (group 5)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Testing for anti‐HAV immunoglobulin M (IgM)
Number of subjects: 114
Study: 6746968

Group type: EXPERIMENTAL
Intervention: Whitaker Index of Schizophrenic Thinking (WIST)
Number of subjects: 85

Group type: COMPARATOR
Intervention: 13 different interview systems for diagnosing schizophrenic disorders
Number of subjects: 85
Study: 31266520

Group type: EXPERIMENTAL
Intervention: Triclosan-coated poliglecaprone 25 sutures
Number of subjects: 364

Group type: COMPARATOR
Intervention: Un-coated suture material
Number of subjects: 364
Study: 29720208

Group type: EXPERIMENTAL
Intervention: Smartphone-based ecological momentary assessment and intervention (EMA/I) in conjunction with a four-session intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 34
Study: 26020827

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% gel
Number of subjects: 233

Group type: COMPARATOR
Intervention: Prednisolone acetate 1% solution
Number of subjects: 233
Study: 24320999

Group type: EXPERIMENTAL
Intervention: Zumba training (twice a week for 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 21669534

Group type: EXPERIMENTAL
Intervention: 20 ml 0.5% plain bupivacaine
Number of subjects: 44

Group type: COMPARATOR
Intervention: 20 ml normal saline (Control)
Number of subjects: 44
Study: 19683149

Group type: EXPERIMENTAL
Intervention: AcrySof single-piece intraocular lens (IOL) implantation in myopia group
Number of subjects: 100

Group type: COMPARATOR
Intervention: AcrySof single-piece intraocular lens (IOL) implantation in control group
Number of subjects: 100
Study: 17296394

Group type: EXPERIMENTAL
Intervention: Sonourethrography
Number of subjects: 93

Group type: COMPARATOR
Intervention: Radio urethrography
Number of subjects: 93
Study: 15464704

Group type: EXPERIMENTAL
Intervention: Enhanced care (usual care plus a coordinator for follow-up appointments and reminders)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Enhanced care
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 125
Study: 11345497

Group type: EXPERIMENTAL
Intervention: VDT with luminance of 90 cd m(‐2) without city noise
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: VDT with luminance of 20 cd m(‐2) without city noise
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: VDT with luminance of 90 cd m(‐2) with city noise of 70 dB(A)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: VDT with luminance of 20 cd m(‐2) with city noise of 70 dB(A)
Number of subjects: 4
Study: 9531132

Group type: EXPERIMENTAL
Intervention: Bupivacaine/morphine (1 mg morphine with 40 mL of 0.25% bupivacaine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine (40 mL of 0.25% bupivacaine)
Number of subjects: 50
Study: 8796759

Group type: EXPERIMENTAL
Intervention: Elective vacuum extraction
Number of subjects: 1428

Group type: COMPARATOR
Intervention: Normal spontaneous vaginal delivery
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: Vacuum extraction in suspected fetal distress
Number of subjects: 1428
Study: 2158614

Group type: EXPERIMENTAL
Intervention: cisplatin-vinblastine
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: cisplatin-ara-C
Number of subjects: 151
Study: 7193030

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide in patients with impaired liver function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide in an anuric patient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 0
Study: 31529622

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 5236

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 5236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5236

Group type: EXPERIMENTAL
Intervention: Lasmiditan (50, 100, or 200 mg)
Number of subjects: 5236

Group type: EXPERIMENTAL
Intervention: Lasmiditan (100 or 200 mg)
Number of subjects: 5236
Study: 26976091

Group type: EXPERIMENTAL
Intervention: Escitalopram, 10 mg/7 days
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 23231574

Group type: EXPERIMENTAL
Intervention: Healthy Weight 2 group-based 4-hr prevention program
Number of subjects: 398

Group type: COMPARATOR
Intervention: Educational brochure control condition
Number of subjects: 398
Study: 21765256

Group type: EXPERIMENTAL
Intervention: Sensory transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 24
Study: 19352302

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 47
Study: 16918728

Group type: EXPERIMENTAL
Intervention: Intragastric saline-intravenous motilin infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intragastric acid-intravenous motilin infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intragastric saline-intravenous motilin infusion and intragastric acid-intravenous saline infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (intragastric saline-intravenous saline)
Number of subjects: 10
Study: 15579527

Group type: EXPERIMENTAL
Intervention: Tapering of prednisolone (TAP) from 16 mg (range 10 to 30) to 9 mg (range 5 to 12.5) daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no tapering of prednisolone)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Steroid withdrawal (SW) of 5 mg prednisolone
Number of subjects: 57
Study: 11800172

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 10322888

Group type: EXPERIMENTAL
Intervention: Combined TCM-WM therapy (TCM-Tangxinshen, TXS) for three months, alongside WM for blood sugar control.
Number of subjects: 60

Group type: COMPARATOR
Intervention: WM alone for three months.
Number of subjects: 60
Study: 8465163

Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no preoperative therapy)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups (after surgery)
Number of subjects: 39
Study: 3517560

Group type: EXPERIMENTAL
Intervention: 50 mg BAY m1099
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 10 mg BAY o1248
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31117920

Group type: EXPERIMENTAL
Intervention: SPG stimulation
Number of subjects: 253

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: SPG stimulation (in patients with confirmed cortical involvement)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Sham control (in patients with confirmed cortical involvement)
Number of subjects: 253
Study: 29908954

Group type: EXPERIMENTAL
Intervention: Foster Care Group (FCG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Care as Usual Group (CAUG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Never-Institutionalized Group (NIG)
Number of subjects: 0
Study: 27670388

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) performed three times at intervals of 3 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Local subacromial injection (corticosteroid and local anesthetic)
Number of subjects: 61
Study: 25448627

Group type: EXPERIMENTAL
Intervention: DVD-delivered exercise intervention for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attentional control condition
Number of subjects: 0
Study: 22949279

Group type: EXPERIMENTAL
Intervention: Web-based intervention with e-mail discussion
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard care (not explicitly mentioned)
Number of subjects: 73
Study: 20067988

Group type: EXPERIMENTAL
Intervention: High dose aprotinin (75,000 KIU/kg intra- and postoperatively)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Low dose aprotinin (25,000 KIU/kg postoperatively)
Number of subjects: 399

Group type: COMPARATOR
Intervention: High dose aprotinin (75,000 KIU/kg)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Low dose aprotinin (25,000 KIU/kg)
Number of subjects: 399
Study: 17625124

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a and ribavirin for 16 weeks
Number of subjects: 1469

Group type: COMPARATOR
Intervention: Peginterferon alfa-2a and ribavirin for 24 weeks
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a and ribavirin for 16 weeks (with pretreatment serum HCV RNA level of 400,000 IU/ml or less)
Number of subjects: 1469

Group type: COMPARATOR
Intervention: Peginterferon alfa-2a and ribavirin for 24 weeks (with pretreatment serum HCV RNA level of 400,000 IU/ml or less)
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a and ribavirin for 16 weeks (with rapid virologic response)
Number of subjects: 1469

Group type: COMPARATOR
Intervention: Peginterferon alfa-2a and ribavirin for 24 weeks (with rapid virologic response)
Number of subjects: 1469
Study: 16206505

Group type: EXPERIMENTAL
Intervention: BCAA (branched-chain amino acid) granules at 12 g/day for 2 years
Number of subjects: 646

Group type: COMPARATOR
Intervention: Diet therapy with defined daily food intake (1.0-1.4 g protein kg(‐1) day(‐1) including BCAA preparation and 25-35 kcal kg(‐1) day(‐1))
Number of subjects: 646
Study: 11996327

Group type: EXPERIMENTAL
Intervention: Fiduxosin (30 mg) under nonfasting conditions
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fiduxosin (30 mg) under fasting conditions
Number of subjects: 14
Study: 10825862

Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 63
Study: 8535198

Group type: EXPERIMENTAL
Intervention: Autoimmune phenomena (AP)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Clinical autoimmune phenomena (CAP)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Immunohaematological phenomena (IHP)
Number of subjects: 626
Study: 2027271

Group type: EXPERIMENTAL
Intervention: Enteric-coated calcium carbonate (3.6 g/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Gastric-coated calcium carbonate (3.1-3.6 g/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Aluminium hydroxide (2.9 g/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (3.1-3.6 g/d)
Number of subjects: 21
Study: 6955127

Group type: EXPERIMENTAL
Intervention: Preventive regimen including chairside education, dietary advice, oral hygiene instruction, and home consumption of a 1 mg fluoride tablet daily
Number of subjects: 242

Group type: COMPARATOR
Intervention: Routine operative treatment needed to maintain dental fitness (Control)
Number of subjects: 242
Study: 31438967

Group type: EXPERIMENTAL
Intervention: Nurses' assessment of AEs
Number of subjects: 334

Group type: COMPARATOR
Intervention: Physicians' assessment of AEs
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Nurses' severity scores for symptomatic AEs
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Agreement on moderate or worse AEs
Number of subjects: 334
Study: 28162930

Group type: EXPERIMENTAL
Intervention: Intracoronary stem cell therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 25655011

Group type: EXPERIMENTAL
Intervention: Women after myocardial infarction
Number of subjects: 14503

Group type: EXPERIMENTAL
Intervention: Women after myocardial infarction (echocardiographic study subset)
Number of subjects: 14503

Group type: COMPARATOR
Intervention: Men after myocardial infarction
Number of subjects: 14503
Study: 24176222

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 750 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: IV ceftriaxone 2 grams daily for four weeks
Number of subjects: 0
Study: 21254841

Group type: EXPERIMENTAL
Intervention: Once weekly measurement and report online (Group A)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Twice weekly measurement and report online (Group B)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional treatment with INR measurement in the lab every 4 weeks (Group C)
Number of subjects: 140
Study: 19496683

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg), 10% caprylate/chromatography purified, 1 g/kg every 3 weeks
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 17537742

Group type: EXPERIMENTAL
Intervention: High sensitivity C-reactive protein (hs-CRP) measured at baseline
Number of subjects: 97
Study: 14986784

Group type: EXPERIMENTAL
Intervention: Ignatia amara containing complex homeopathic remedies (IACCHR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pharmaceuticals
Number of subjects: 0
Study: 11510064

Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microgram.kg‐1, i.v.) and propofol (1.5 mg.kg‐1.h‐1) during insertion of epidural catheters
Number of subjects: 16

Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 16
Study: 9517606

Group type: EXPERIMENTAL
Intervention: budesonide
Number of subjects: 44

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study: 8112186

Group type: EXPERIMENTAL
Intervention: 1,674 kJ/day (400 kcal)
Number of subjects: 93

Group type: COMPARATOR
Intervention: 4,185 kJ/day (1,000 kcal)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 1,674 to 4,185 kJ (400 to 1,000 calories)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 4,185 kJ (1,000 calories) throughout
Number of subjects: 93
Study: 3280192

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination therapy (Metoprolol + Nifedipine)
Number of subjects: 11
Study: 30015681

Group type: EXPERIMENTAL
Intervention: Customized adaptive quizzing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preintervention cohort (no adaptive quizzing)
Number of subjects: 0
Study: 27473562

Group type: EXPERIMENTAL
Intervention: Plant sterol ester supplemented margarine (3g plant sterols per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 16
Study: 25251767

Group type: EXPERIMENTAL
Intervention: Cysteamine 5% cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23759406

Group type: EXPERIMENTAL
Intervention: Skype condition (Internet‐based videoconferencing)
Number of subjects: 71

Group type: COMPARATOR
Intervention: In-clinic condition
Number of subjects: 71